2011 Reaxys PhD Prize opens for entries
Global competition for PhD students of chemistry
The prize will be awarded for original and innovative research in organic, organometallic and inorganic chemistry to the candidates that demonstrate excellence in methodology and approach.
Three prizewinners will each receive US$2,000 and will be invited to present their research at the Winners’ Symposium during the 14th Asian Chemical Congress, which takes place from 5–8 September in Bangkok, Thailand.
David Evans, scientific affairs director at Elsevier Properties, said: ‘The Reaxys PhD Prize celebrates innovation and creativity in chemistry research from around the world, values which lie at the heart Reaxys itself.’
He continued: ‘In 2010 we received more than 300 submissions from around the world covering the breadth of modern chemistry. The quality of research was outstanding, and the finalists and winners are clearly at the cutting edge of chemistry research. A high bar has been set for 2011.’
All entries will be evaluated by a review board of leading international chemists, chaired by the Professor A G M Barrett, Imperial College London, UK; Professor B M Trost, Stanford University, US; and Professor H N C Wong, Chinese University of Hong Kong, China, who are members of the Reaxys Advisory Board.
All submissions must include a PhD Supervisor letter of recommendation, a CV and a representative peer-reviewed piece of published research. Entries should be submitted by 28 February to the Reaxys PhD Prize website.
Elsevier Properties SA a division of scientific publisher Reed Elsevier that manages intellectual property. It owns the PharmaPendium, Beilstein and Reaxys databases.
You may also like
Research & Development
Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform
Irish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing
Research & Development
Phesi analysis finds 6.7% of global clinical trials affected by Middle East disruption
A Phesi analysis of more than 65,000 active clinical trials has found that 4361 studies are impacted by Middle East disruption, with Phase III oncology trials most exposed and all top ten global pharma companies holding significant investigator site presence in affected countries
Manufacturing
Degasser for volatile and aggressive solvents
Biotech Fluidics announce the DEGASi Integration HFIP - a high-performance online system designed to efficiently degas even the toughest solvents. This unique degasser is fully compatible with a wide range of volatile and aggressive liquids including Hexafluoroisopropanol (HFIP) and silanes but can also manage all other solvents used for GPC/SEC and HPLC
Research & Development
Symeres joins forces with Ambagon Therapeutics to expand molecular glue research in colorectal cancer
The pair will aim to explore a new class of small molecules, known as molecular glues, for potential therapeutic use in colorectal cancer and other hard-to-target diseases as an alternative to traditional therapies
Research & Development
University of Exeter leads £4.5m Wellcome-funded initiative to develop bioimaging tools for fungal pathogens
An international collaboration spanning the universities of Exeter, Edinburgh and Cape Town has secured £4.5m to develop specialist bioimaging tools for WHO-priority fungal pathogens